Morgan Stanley Downgrades IGM Biosciences to Equal-Weight, Lowers Price Target to $38
Morgan Stanley analyst Michael Ulz downgrades IGM Biosciences (NASDAQ:IGMS) from Overweight to Equal-Weight and lowers the price target from $100 to $38.
59 Biggest Movers From Yesterday
Gainers
SeaChange International, Inc. (NASDAQ: SEAC) jumped 128.8% to $1.72 following Bloomberg report suggesting that social video app Triller is in merger talks with Seachange.
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to 4,684.47.
Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge
Midway through trading Monday, the Dow traded down 0.81% to 35,679.10 while the NASDAQ fell 0.78% to 15,509.01. The S&P also fell, dropping 0.67% to 4,680.56.
40 Stocks Moving In Monday’s Mid-Day Session
Gainers
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.
Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals
Following the market opening Monday, the Dow traded down 0.65% to 35,736.04 while the NASDAQ fell 0.26% to 15,590.13. The S&P also fell, dropping 0.46% to 4,690.48.
Where IGM Biosciences Stands With Analysts
Within the last quarter, IGM Biosciences (NASDAQ:IGMS) has observed the following analyst ratings:
Jefferies Maintains Buy on IGM Biosciences, Raises Price Target to $126
Jefferies analyst Chris Howerton maintains IGM Biosciences (NASDAQ:IGMS) with a Buy and raises the price target from $101 to $126.